Cost utility of lateral-flow urine lipoarabinomannan for tuberculosis diagnosis in HIV-infected African adults

International Journal of Tuberculosis and Lung Disease

Volumn 17, Issue 4, 2013, Pages 552-558

  Sun, D ^a   Dorman, S ^b,c,d   Shah, M ^b,c,d   Manabe, Y C ^c,e   Moodley, V M ^f,g   Nicol, M P ^f   Dowdy, D W ^a,c,d  

^a JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c JOHNS HOPKINS UNIVERSITY   (United States)

^d Tuberculosis Clinical Diagnostics Research Consortium   (United States)

^e Infectious Diseases Institute   (Uganda)

^f UNIVERSITY OF CAPE TOWN   (South Africa)

^g UNIVERSITY OF CAPE TOWN   (South Africa)

Author keywords

Diagnostic tests and procedures; Economic; HIV; Models; South africa; Tuberculosis; Uganda

Indexed keywords

LIPOARABINOMANNAN; TUBERCULOSTATIC AGENT;

AFRICAN; ANTIMICROBIAL THERAPY; ARTICLE; BACTERIUM DETECTION; CD4 LYMPHOCYTE COUNT; CLINICAL FEATURE; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; COST UTILITY ANALYSIS; DIAGNOSTIC TEST ACCURACY STUDY; DRUG COST; DRUG INDICATION; ETHNIC GROUP; GEOGRAPHIC DISTRIBUTION; HEALTH CARE COST; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LATERAL FLOW URINE LIPOARABINOMANNAN TEST; MAJOR CLINICAL STUDY; ONSET AGE; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; SENSITIVITY AND SPECIFICITY; SOUTH AFRICA; SPUTUM SMEAR; TUBERCULOSIS; TUBERCULOSIS CONTROL; UGANDA;

ADULT; BIOLOGICAL MARKERS; CD4 LYMPHOCYTE COUNT; COINFECTION; COST-BENEFIT ANALYSIS; DECISION SUPPORT TECHNIQUES; DEVELOPING COUNTRIES; HEALTH CARE COSTS; HEALTH CARE SURVEYS; HIV INFECTIONS; HUMANS; LIPOPOLYSACCHARIDES; MODELS, ECONOMIC; MONTE CARLO METHOD; MULTIVARIATE ANALYSIS; PREDICTIVE VALUE OF TESTS; PREVALENCE; PROGNOSIS; SOUTH AFRICA; TUBERCULOSIS; UGANDA; URINALYSIS; YOUNG ADULT;

EID: 84875412263     PISSN: 10273719     EISSN: None     Source Type: Journal    
DOI: 10.5588/ijtld.12.0627     Document Type: Article

References (35)

1. Diedrich C R, Flynn J L. HIV-1/Mycobacterium tuberculosis co-infection immunology: how does HIV-1 exacerbate tuberculosis? Infect Immun 2011; 79: 1407-141-7.
2. Bock N N, Jensen P A, Miller B, Nardell E. Tuberculosis infection control in resource-limited settings in the era of expanding HIV care and treatment. J Infect Dis 2007; 196 (Suppl 1): S108-S11-3.
3. Getahun H, Gunneberg C, Granich R, Nunn P. HIV infectionassociated tuberculosis: the epidemiology and the response. Clin Infect Dis 2010; 50 (Suppl 3): S201-S20-7.
4. Lawn S D, Wood R. Tuberculosis in antiretroviral treatment services in resource-limited settings: addressing the challenges of screening and diagnosis. J Infect Dis 2011; 204 (Suppl 4): S1159-S116-7.
5. Anandaiah A, Dheda K, Keane J, et al. Novel developments in the epidemic of human immunodeficiency virus and tuberculosis coinfection. Am J Respir Crit Care Med 2011; 183: 987-99-7.
6. Cox J A, Lukande R L, Lucas S, et al. Autopsy causes of death in HIV-positive individuals in sub-Saharan Africa and correlation with clinical diagnoses. AIDS Rev 2010; 12: 183-19-4.
7. Dowdy D W, O'Brien M A, Bishai D. Cost-effectiveness of novel diagnostic tools for the diagnosis of tuberculosis. Int J Tuberc Lung Dis 2008; 12: 1021-102-9.
8. Vassall A, van Kampen S, Sohn H, et al. Rapid diagnosis of tuberculosis with the Xpert MTB/RIF assay in high burden countries: a cost-effectiveness analysis. PLoS Med 2011; 8: e100112-0.
9. Andrews J R, Lawn S D, Rusu C, et al. The cost-effectiveness of routine tuberculosis screening with Xpert MTB/RIF prior to initiation of antiretroviral therapy in South Africa: a modelbased analysis. AIDS (London, UK) 2012; 26: 987-99-5.
10. Hughes R, Wonderling D, Li B, Higgins B. The cost-effectiveness of nucleic acid amplification techniques for the diagnosis of tuberculosis. Respir Med 2012; 106: 300-30-7.
11. Minion J, Leung E, Talbot E, et al. Diagnosing tuberculosis with urine lipoarabinomannan: systematic review and metaanalysis. Eur Respir J 2011; 38: 1398-140-5.
12. Chan J, Fan X D, Hunter S W, Brennan P J, Bloom B R. Lipoarabinomannan, a possible virulence factor involved in persistence of Mycobacterium tuberculosis within macrophages. Infect Immun 1991; 59: 1755-176-1.
13. Lawn S D, Kerkhoff A D, Vogt M, Wood R. Diagnostic accuracy of a low-cost, urine antigen, point-of-care screening assay for HIV-associated pulmonary tuberculosis before antiretroviral therapy: a descriptive study. Lancet Infect Dis 2012; 12: 201-20-9.
14. Shah M, Martinson N A, Chaisson R E, et al. Quantitative analysis of a urine-based assay for detection of lipoarabinomannan in patients with tuberculosis. J Clin Microbiol 2010; 48: 2972-297-4.
15. Boehme C, Molokova E, Minja F, et al. Detection of mycobacterial lipoarabinomannan with an antigen-capture ELISA in unprocessed urine of Tanzanian patients with suspected tuberculosis. Trans R Soc Trop Med Hyg 2005; 99: 893-90-0.
16. Dorman S, Manabe Y, Nicol M, et al. Accuracy of Determine LAM lateral fl ow test for diagnosis of TB in HIV+ adults: interim results of a multicenter study. 19th Conference on Retroviruses and Opportunistic Infections, Seattle, WA, USA, 5-8 March 2012 [Abstract 149aLB]. http://retroconference.org/2012b/ Abstracts/45385.htm Accessed January 201-3.
17. World Health Organization. Global tuberculosis control 2011. WHO/HTM/TB/2011.16. Geneva, Switzerland: WHO, 2011. http://www.who.int/tb/ publications/global-report/en/Accessed January 201-3.
18. Shang P, Xia Y, Liu F, et al. Incidence, clinical features and impact on anti-tuberculosis treatment of anti-tuberculosis drug induced liver injury (ATLI) in China. PLoS ONE 2011; 6: e2183-6.
19. Field N, Murray J, Wong M L, et al. Missed opportunities in TB diagnosis: a TB process-based performance review tool to evaluate and improve clinical care. BMC Public Health 2011; 11: 12-7.
20. Martinson N A, Karstaedt A, Venter W F, et al. Causes of death in hospitalized adults with a pre-mortem diagnosis of tuberculosis: an autopsy study. AIDS 2007; 21: 2043-205-0.
21. Lawn S D, Ayles H, Egwaga S, et al. Potential utility of empirical tuberculosis treatment for HIV-infected patients with advanced immunodeficiency in high TB-HIV burden settings. Int J Tuberc Lung Dis 2011; 15: 287-29-5.
22. World Health Organization. The global burden of disease: 2004 update. Geneva, Switzerland: WHO, 2004. http://www.who.int/healthinfo/global-burden- disease/2004-report-update/en/index.html Accessed January 201-3.
23. Actuarial Society of South Africa. ASSA2008 AIDS and demographic model. Cape Town, South Africa: Actuarial Society of South Africa, 2011. http://aids.actuarialsociety.org. za/ASSA2008-Model-3480.htm Accessed January 201-3.
24. Mills E J, Bakanda C, Birungi J, et al. Mortality by baseline CD4 cell count among HIV patients initiating antiretroviral therapy: evidence from a large cohort in Uganda. AIDS 2011; 25: 851-85-5.
25. Brinkhof M W G, Boulle A, Weigel R, et al. Mortality of HIVinfected patients starting antiretroviral therapy in sub-Saharan Africa: comparison with HIV-unrelated mortality. PLoS Med 2009; 6: e100006-6.
26. May M, Boulle A, Phiri S, et al. Prognosis of patients with HIV-1 infection starting antiretroviral therapy in sub-Saharan Africa: a collaborative analysis of scale-up programmes. Lancet 2010; 376: 449-45-7.
27. Abdool Karim S S, Naidoo K, Grobler A, et al. Integration of antiretroviral therapy with tuberculosis treatment. N Engl J Med 2011; 365: 1492-150-1.
28. World Health Organization. Tuberculosis finance profile-Uganda. Geneva, Switzerland: WHO, 2013. https://extranet. who.int/sree/Reports?op= Replet&name=%2FWHO-HQ-Reports%2FG2%2FPROD%2FEXT%2FTBFinancingCountry Profile&ISO2=UG&outtype=html Accessed January 201-3.
29. Russell L B, Gold M R, Siegel J E, Daniels N, Weinstein M C. The role of cost-effectiveness analysis in health and medicine. Panel on Cost-Effectiveness in Health and Medicine. JAMA 1996; 276: 1172-117-7.
30. Boehme C C, Nicol M P, Nabeta P, et al. Feasibility, diagnostic accuracy, and effectiveness of decentralised use of the Xpert MTB/RIF test for diagnosis of tuberculosis and multidrug resistance: a multicentre implementation study. Lancet 2011; 377: 1495-150-5.
31. The World Bank. South Africa data. Washington DC, USA: World Bank, 2013. http://data.worldbank.org/country/southafrica Accessed January 201-3.
32. Shah M, Variava E, Holmes C B, et al. Diagnostic accuracy of a urine lipoarabinomannan test for tuberculosis in hospitalized patients in a high HIV prevalence setting. J Acquir Immune Defic Syndr 2009; 52: 145-15-1.
33. Manosuthi W, Chottanapand S, Thongyen S, Chaovavanich A, Sungkanuparph S. Survival rate and risk factors of mortality among HIV/tuberculosis-coinfected patients with and without antiretroviral therapy. J Acquir Immune Defic Syndr 2006; 43: 42-4-6.
34. Bongaarts J, Over M. Public health. Global HIV/AIDS policy in transition. Science 2010; 328: 1359-136-0.
35. Talbot E, Munseri P, Teixeira P, et al. Test characteristics of urinary lipoarabinomannan and predictors of mortality among hospitalized HIV-infected tuberculosis suspects in Tanzania. PLoS ONE 2012; 7: e3287-6.